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ABSTRACT: The efficiency of a drug is usually highly dependent on the way it is administered or delivered. As such, targeted-therapy, which 
requires conceiving drug-delivery vehicles that will change their state from a relatively stable structure with a very slow leak-rate to an unstable 
structure with a fast release, clearly improves the pharmacokinetics, the absorption, the distribution, the metabolism and the therapeutic index of a 
given drug. In this context, we have developed a particularly effective double stimuli-responsive drug-delivery method allowing an ultrasound-
induced release of a monomethylauristatin E-glucuronide prodrug and its subsequent activation by a β-glucuronidase. This led to an increase of 
cytotoxicity of about 80% on cancer cells. 
1. Introduction 
 
The development of ‘smart’ carriers programmed for the 
localized delivery of highly cytotoxic drugs in response to 
extracorporeal physical stimuli offers promises for cancer 
chemotherapy [1-3]. Such systems are indeed designed to 
release most, if not all, the administered drug dose directly at 
the tumor site thereby avoiding any undesired toxicity in 
healthy tissues. To date, several stimuli-triggered release 
methods have been reported in the literature; these include 
ultrasound-activated structures [4,5], especially microbubbles 
[6-10] or thermosensitive liposomes [11-16]. Considering that 
ultrasound benefit from their high spatial (millimeter) and 
temporal (microsecond) resolution, their depth of penetration 
(up to 10 cm) and their ubiquity in hospitals worldwide [17], 
they represent a method of choice for achieving optimal spa-
tial- and temporal-controlled release in the context of drug 
delivery. Within this framework, we previously demonstrated 
that ultrasound-sensitive perfluorocarbon (PFC) composite 
droplets injected systemically could transport large payload of 
fluorescein and deliver their content in vivo using a clinical 
ultrasound scanner with a millimetric resolution [18,19]. This 
strategy was also used by Fabiilli and co-workers to carry and 
release chlorambucil, a lipophilic chemotherapeutic [20], and 
thrombin, a serine protease used in the treatment of pseudoan-
eurysms [21]. More recently, Fabiilli et al. also reported the 
biodistribution of such composite droplets of perfluorocarbon 
(6 µm or less in diameter) in rats [22]. While this technology 
appeared very useful for internal tattooing of tissues, the slow 
leakage of the encapsulated compound observed from un-
induced droplets appeared as a potential drawback to envision 
the adaptation of this concept to the delivery of highly toxic 
anticancer agents. Since the problem of unspecific release is 
inherent to all the carriers developed so far [23], we herein 
propose to evaluate a new generation of ultrasound-sensitive 
drug delivery systems based on the encapsulation, within 
ultrasound-sensitive perfluorocarbon composite droplets, of a 
none/less active drug precursor instead of the parent drug. 
Indeed, by specifically manufacturing the active agent within 
the ultrasound focus, not only would we be able to exclusively 
limit its activity within the zone delineated on the imaging 
scanner, but we would also limit any undesired side effects, 
which could occur downstream. 
In order to evaluate the feasibility of this new drug deliv-
ery concept, we previously demonstrated that we were able to 
trigger a spontaneous reaction with a high spatial and temporal 
control [24]. A first proof of concept was achieved by promot-
ing a Cu-free click reaction using a single ultrasound pulse 
specifically within the focus of a transducer (0.6 mm in width) 
and within a time frame of less than 3 ms. Since these acoustic 
 
pulses were produced by a clinical ultrasonic scanner, the 
generation of a chemical reaction deep into the tissue could 
clearly be envisioned. We therefore decided to test this hy-
pothesis by investigating the in vitro ultrasound-induced acti-
vation of a glucuronide anticancer prodrug on cancer cells. We 
report here the results of our endeavor. 
 
2. Results and discussion 
 
A glucuronide prodrug of monomethylauristatin E 
(MMAE-glu) [25-32] was chosen to perform this study 
[33,34]. Indeed, MMAE is a potent antimitotic agent currently 
employed in human for the treatment of lymphomas under the 
form of the brentuximab vedotin, an antibody-drug conjugate 
that reached the market in 2011 [35]. In contrast, the free 
MMAE cannot be used clinically because of its excessive 
toxicity towards non-malignant tissues. Under such circum-
stances, encapsulation of MMAE-glu instead of MMAE brings 
several advantages. Indeed, as the prodrug is much more hy-
drophilic than the parent drug, it is therefore a much better 
candidate for encapsulation in aqueous composite droplets. In 
addition, the glucuronide prodrug is 40-100 fold less toxic 
than the parent drug, which will largely reduce any non-
selective toxicity caused by potential leakage of the composite 
droplets outside the area of interest and therefore limit poten-
tial damages of surrounding healthy tissues. Moreover, since 
the β-glucuronidase is over-expressed in the microenvironment 
of almost all solid tumors [26,36,37], ultrasound-triggered 
release of the prodrug in the vicinity of the tumor mass should 
be followed by the local enzyme-mediated release of the ac-
tive drug via the self-immolative mechanism illustrated in 




Fig. 1. Structure of MMAE glucuronide prodrug (MMAE-glu) 
and its self-immolative mechanism upon β-glucuronidase 
activation. 
 
This strategy has proved its efficacy in numerous animal 
models over the years [29,37,40-45], as for example showed 
by Papot and co-workers in mice  [30]. These prodrugs are 
rapidly eliminated by the kidneys, thus lowering their concen-
tration in tumors. Nevertheless, the localized ultrasound-
triggered delivery of an encapsulated prodrug should also 
improve its therapeutic index by both enhancing its concentra-
tion in the vicinity of the targeted tissues and minimizing its 
metabolization. 
We first encapsulated solutions of MMAE and glucuronyl-
ated MMAE (at a concentration of 0.1 mmol.L-1 in a 
RPMI1640 cell culture) in the inner phase of composite drop-
lets of perfluorocarbon. These droplets were produced with a 
microfluidic system composed of parallel step emulsifiers 
(see experimental protocols for more details). A specific mi-
crofluidic device could yield a monodisperse population of 
droplets with sizes varying between 3 and 8 µm. In the context 
of this study, the droplets had a mean diameter of 3.3 µm with 
a standard deviation of 0.3 µm. Most importantly, these drop-
lets are comparable in size and formulation to those previously 
exploited in-vivo by our group [18,19] and by the group of 
Fabiilli [20-22]. The in vitro study was carried out in 96-well 
plates specially designed to meet both the requirements of 
acoustic wave propagation and the biological needs (sterile 
medium, optical lecture of cell proliferation). Hence, the regu-
lar thick bottom of the plates was replaced by a thin Mylar-
membrane. Those plates were immersed in a water bath ther-
mo-stated at 37 °C, in which a single-element transducer was 
fixed at a distance from the plate corresponding to the focal 
distance of the transducer (36 mm). Four acoustic pulses were 
focused in each well (5 cycles ≈ 11 MPa PNP, 1.5 MHz, each 
pulse approximately one second apart). 
Two different protocols were implemented (see experi-
mental protocols for more details). In the first one, referred to 
as the “contact” protocol, KB cancer cells were grown in the 
wells for a 24 h period, before the droplets were added. Ultra-
sound pulses were then focused in the well in order to partially 
release the encapsulated compounds and the resulting suspen-
sion of unreleased droplets was left in contact with the cells 
and incubated at 37 °C for 72 h. The measurement of cell 
viability was then obtained through a XTT colorimetric assay. 
In the second protocol, referred to as the “transfer” protocol, a 
suspension of composite droplets was poured in an empty 
well. Part of the droplet’s population was released using the 
same acoustic protocol. Only the droplets’ supernatant, and 
therefore the ultrasound-released compounds, were transferred 
to the cancer cells, while the residual unreleased droplets were 
eliminated. After an incubation period of 72 h at 37 °C, cell 
proliferation was evaluated using the same XTT assay. 
In order to rule out false positives, a number of control ex-
periments were first carried out. It was indeed essential to 
assess the effect of the ultrasound pulses, the droplets’ compo-
sition and the ultrasound-mediated vaporization protocol on 
the viability of KB cells. In other terms, we needed to ensure 
that the cytotoxic effect we would be measuring would be 
solely resulting from the local release of the prodrug and its 
specific activation. Interestingly, ultrasound exposure showed 
no significant alteration of the cell viability in all cases. Simi-
larly, prolonged exposure ("contact" protocol, 72 h exposure) 
to a high concentration (0.5% v/v) of droplets containing only 
cell culture medium (CM) did not lead to significant change in 
mortality. Finally, the combination of droplets and ultrasound 
to induce local PFC vaporization appeared to be harmless as 
well (Figure 2). 
Considering the results of the control experiments, we pur-
sued our investigation further by studying the in situ release 
and activation of both monomethylauristatin E (MMAE) and 
its glucuronide analogue (MMAE-glu). To do so, we evaluated 
composite droplets containing MMAE and MMAE-glu, both 
prepared at the same initial inner concentration of 0.1 mM. 
A suspension of droplets at 0.01% v/v was used in the 
course of this study. Regarding the in situ activation of 
MMAE-glu by the β-glucuronidase (β-glu), Legigan et al. [30] 
showed that complete conversion of the prodrug intro MMAE 














































           
 
Fig. 2.  Control experiments (“contact” protocol), using drop-
lets containing pure cell culture medium (CM). When rele-
vant, 4 ultrasound pulses were focused on the corresponding 
wells (5 cycles, 11 MPa PNP, 1.5 MHz). Cell viability was 
measured after a 72 h incubation period at 37 °C through a 
XTT colorimetric assay. All cell viability measurements were 
normalized by the viability obtained for non-treated cells. 
ns: no statistical difference. Experiment repeated n times. 
   
 
 
Fig. 4. Study of the droplets’ stability and of the leakage phe-
nomenon using the “transfer” protocol. Droplets containing 
either MMAE or MMAE-glu were used. Cell viability was 
measured after a 72 h incubation period at 37 °C through a XTT 
colorimetric assay without adding any β-glucuronidase in the 
wells. All cell viability measurements were normalized by the 
viability obtained for non-treated cells. Statistical significance 
was determined by ANOVA test and Dunnet post-test. 
* p<0.05, ** p<0.01, *** p<0.001, ns: no statistical difference. 
Experi-ment repeated 4 times (n=4). 
  
 
Fig. 3. In situ activation experiments (“transfer” and "contact" 
protocols), using droplets containing MMAE and MMAE-glu 
respectively. When relevant, β-glucuronidase was added 
(40u/well) and/or 4 ultrasound pulses were focused on the 
corresponding wells (5 cycles, 11 MPa PNP, 1.5 MHz). Cell 
viability was measured after a 72 h incubation period at 37 °C 
through a XTT colorimetric assay. All cell viability measure-
ments were normalized by the viability obtained for non-treated 
cells. Statistical significance was determined by ANOVA test 
and Dunnet post-test. * p<0.05, ** p<0.01, *** p<0.001, ns: no 
statistical difference. Experiment repeated 4 times (n=4). 
 
       
 
Fig. 5. Study of the droplets’ stability and of the leakage phe-
nomenon using the “transfer” protocol. Droplets containing 
either MMAE or MMAE-glu were used. Cell viability was 
measured after a 72 h incubation period at 37 °C through a 
XTT colorimetric assay without adding any β-glucuronidase 
in the wells. All cell viability measure-ments were normal-
ized by the viability obtained for non-treated cells. Statistical 
significance was determined by ANOVA test and Dunnet 
post-test. * p<0.05, ** p<0.01, *** p<0.001, ns: no statistical 
differ-ence. Experiment repeated 4 times (n=4). 
achieved within the first 10 minutes after contact. We were 
then able to compare the normalized cell viability of cells 
exposed to the ultrasound-released content of MMAE-glu 
droplets to the viability of cells exposed to both 
β-glucuronidase and ultrasound-released MMAE-glu. As a 
general trend, no statistically significant alteration of the cell 
viability was observed in the first case, while the exposure to 
both enzyme and released MMAE-glu led to a drop in viability 
of about 80% as a result of the in situ β-glucuronidase-
catalyzed release of MMAE (Figure 3). A similar behavior 
was also observed in the case of a prolonged residence time of 
the droplets in the culture wells ("contact" protocol, 72 h ex-
posure). Interestingly, however, the ultrasound-release of the 
encapsulated parent drug led to a smaller antiproliferative 
effect, which is most probably due to a slight difference in the 
respective MMAE and MMAE-glu droplets’ formulation; the 
prodrug being more hydrophilic than the parent drug.  
Concerned by the potential damage that could cause pas-
sive leakage of a highly toxic drug such as MMAE, we next 
evaluated the impact of the leakage of MMAE-glu containing 
droplets. To this end, KB cells were incubated for 72 h with 
increased concentrations of droplets containing either MMAE 
or MMAE-glu ("transfer" protocol) without adding any 
β-glucuronidase. As shown in Figure 4, increasing the concen-
tration of MMAE-containing droplets dramatically affected 
the cell viability. In sharp contrast, MMAE-glu droplets exhib-
ited no significant toxicity until the highest tested concentra-
tion of 0.5 % v/v thus showcasing the benefits of encapsulat-
ing the prodrug instead of the parent drug. 
 
After demonstrating that MMAE-glu could be locally reac-
tivated into MMAE upon ultrasound release and subsequent 
β-glucuronidase-mediated activation, and after confirming the 
limited impact of any residual leakage that could potentially 
stem from our prodrug-containing droplets, we brought addi-
tional evidence of the potential of our double-stimuli respon-
sive strategy by showing the importance of the joint 
ultrasound and enzymatic activation. Remarkably, prolonged 
exposure of the cells to the MMAE-glu and MMAE-
containing droplets ("contact" protocol, 72 h exposure) 
showed no statistically relevant drop in cell viability.  
We also compared the viability of the cells treated with 
MMAE-glu-containing droplets in the presence and in the 
absence of β-glucuronidase without using any ultrasound. 
Interestingly, in the case of short-term leakage ("transfer" 
protocol), no significant change in cell viability was observed 
with both droplets in the presence or in the absence of enzyme 
in the culture medium (Figure 5). After a prolonged contact 
time of the MMAE-glu containing droplets with the cells 
("contact" protocol, 72 h exposure), only a minute increase in 
cell mortality was detected, which showcased both the very 
good retention of the encapsulated compounds into the drop-
lets and the absolute necessity of the β-glucuronidase to trig-




In conclusion, we managed to encapsulate an anti-cancer 
agent, monomethylauristatin E (MMAE), and its glucuronide 
prodrug, MMAE-glu, into composite droplets of perfluorohex-
ane. A good retention of those compounds into the droplets 
was observed over three days. Moreover, cytotoxic activity of 
the parent drug MMAE was successfully restored by ultra-
sound-release of MMAE-glu droplets in the presence of 
β-glucuronidase with an 80% increase in cell mortality com-
pared to the ultrasound release in the absence of the enzymatic 
partner. These in vitro results on KB cancer cells clearly vali-
date our proof of concept. In the case of an enzymatic activa-
tion such as the one provided in this study, as the enzyme is 
specific of the extra-tumoral medium, the in vivo activation 
should only occurs on the tumor site. This in situ chemistry 
strategy could potentially be extended to other example of 
prodrug/enzyme couples as well as to other kind of chemically 
activatable systems [46]. 
 
4. Experimental protocols 
 
4.1. Composite droplet preparation. 
 
The composite droplets were fabricated in two steps. First, 
a primary nano-emulsion was obtained by using a sonic tip 
(Branson, 20 kHz, 70% of maximum amplitude, 8 cycles of 
5 sec), with the fluids immersed in ice water. This nano-
emulsion consists of an aqueous solution containing respec-
tively MMAE (0.1 mM) and MMAE-glu (0.1 mM) in cell 
culture medium dispersed in perfluorohexane (FC-72, 3M) and 
stabilized by a fluorinated surfactant (PEG-di-Krytox, RAN 
Biotechnologies, 3% w/v in perfluorocarbon phase). The size 
of these nanoemulsions was evaluated on a Malvern Zetasizer 
Nano ZS. Typical diameter was found to be between 300 and 
500 nm. The primary nano-emulsion was then encapsulated as 
micron-size droplets in a PBS solution (1X from 10X com-
mercial solution), using a microfluidic device based on a par-
allelized system of step emulsifiers. The microfluidic system 
was made of polydimethylsiloxane. The droplets were stabi-
lized by Pluronic-68® (polyoxyethylene-polyoxypropylene 
block copolymer, Sigma-Aldrich, St. Louis, MO, 3% w/v). 
The droplets were collected. Supernatant from the production 
step was removed and replaced by another PBS solution with 
various additives (Pluronic-68®, 3% w/v, Penicil-
lin/Streptomycin 2X, Gentamycin 2X, Kanamycin 2X) to 
prevent any bacterial development. Droplets were then stored 
at 4 °C and used within 48 h. 
 
4.2. Cell culture 
 
KB (human oral squamous carcinoma) cells were grown in 
RPMI 1640 (Invitrogen) supplemented by 10% fetal bovine 
serum and 1% Penicillin/Streptomycin (Lonza) in a humidi-
fied incubator at 37 °C and 5% CO2. KB cells were purchased 
on ATCC (CCL-17) and used at early passages. 
 
4.3. Ultrasound set-up 
 
An ultrasound transducer (2.25 MHz, 38 mm focal length, 
f/d = 1, Imasonics, Voray-sur-l’Ognon, France) was fixed in a 
3D-printed plastic setup, which allowed a 96-well plate im-
mersed in a water bath thermostated at 37 °C to be moved 
through the acoustic focus (Figure 2a). The transducer was 
powered with a 40 dB RF amplifier (TOMCO, Stepney, Aus-
tralia) driven by an arbitrary waveform generator (Tektronix, 
Beaverton, Oregon). Four acoustic pulses (5 cycles, 11 MPa 
PNP, 1.5 MHz) were triggered after aligning the target-well 
with the acoustic focus. The 96 well-plates were bottomless 
plates under which a Mylar membrane was glued under sterile 
conditions to provide an optically and acoustically transparent 
window. 
 
4.4. Contact protocol 
 
KB cells were seeded and grown for 24 h in poly-L-lysine-
coated thin-bottom 96-well plates. After this first incubation 
period at 37 °C, 70 µL of a 0.01 % v/v suspension of droplets 
in cell culture medium was placed in each well, on the cells. 
When relevant, 4 ultrasound pulses were focused on the corre-
sponding wells, followed when necessary by a solution of 
β-glucuronidase (E. coli, 40u/well). The plates were then 
incubated at 37 °C for 72 h, before XTT assay was performed 
to evaluate cell proliferation. 
 
4.5. Transfer protocol 
 
KB cells were seeded and grown for 24 h in regular 96-
well plates. After this first incubation period at 37 °C, 90 µL 
of a 0.01% v/v suspension of droplets in cell culture medium 
was placed in thin-bottom 96-well plates. When relevant, 4 
ultrasound pulses were focused on the corresponding wells 
(5 cycles, 11 MPa PNP, 1.5 MHz). The content of each well 
was centrifuged, and the non-released droplets were eliminat-
ed. Supernatant containing the ultrasound-released compounds 
(70 µL) was then transferred on the KB cells in the regular 
96-well plates, followed when necessary by a solution of 
β-glucuronidase (E. coli, 40 u/well). The plates were then 
incubated at 37 °C for 72 h, before XTT assay was performed 
to evaluate cell proliferation. 
 
 
4.5. Cell viability measurements 
 
The cell viability kit II (XTT, Roche) was used to assess 
cell viability. This assay is based on the cleavage of XTT by 
metabolic active cells resulting in the production of an orange 
formazan dye quantified by spectrophotometry. Assays were 
carried out essentially as described by the manufacturer. Brief-
ly, after the incubation specified in each protocol, 25 µL of the 
XTT labeling mixture were added per well. Cells were further 
incubated for additional 4 h at 37 °C before determination of 
the absorbance at 490 nm (Absorbance was read using a mul-
timode microplate reader (Mithras LB940, Berthold Technol-
ogies). Experiments were performed n times (4 < n < 8) per 
condition. Statistical significance was determined by ANOVA 
test and Dunnet post-test. * p<0.05, ** p<0.01, *** p<0.001, 
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